| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002823 | American Journal of Ophthalmology | 2013 | 9 Pages |
Abstract
Aflibercept therapy appears to be beneficial in a subset of patients with neovascular age-related macular degeneration who exhibit recurrent or resistant intraretinal or subretinal fluid following multiple injections with either bevacizumab or ranibizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Benjamin Bakall, James C. Folk, H. Culver Boldt, Elliott H. Sohn, Edwin M. Stone, Stephen R. Russell, Vinit B. Mahajan,